485 related articles for article (PubMed ID: 24552447)
1. Anti-IL-17 phase II data for psoriasis: A review.
Brown G; Malakouti M; Wang E; Koo JY; Levin E
J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
[TBL] [Abstract][Full Text] [Related]
3. Review of IL-17 inhibitors for psoriasis.
Amin M; Darji K; No DJ; Bhutani T; Wu JJ
J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
[No Abstract] [Full Text] [Related]
4. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
6. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL-23 Phase II Data for Psoriasis: A Review.
Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
9. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
[TBL] [Abstract][Full Text] [Related]
12. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.
Chen Y; Qian T; Zhang D; Yan H; Hao F
Immunotherapy; 2015; 7(9):1023-37. PubMed ID: 26055639
[TBL] [Abstract][Full Text] [Related]
17. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
Yamauchi PS; Bagel J
J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
20. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]